United States Patent 6,875,872: Scope, Claim Strength, and Landscape
US Patent 6,875,872 covers a single chemical invention: a magnesium salt of a specific (−)-enantiomer of a substituted benzimidazole containing a sulfinyl (chiral sulfoxide) linkage and a pyridine substituent, with protection keyed to enantiomeric excess (ee) and crystalline form.
This patent is narrow in chemistry (fixed structure, fixed metal salt, fixed stereochemistry) but can be commercially relevant because the claims push to very high optical purity thresholds (up to ≥99.9% ee) and include crystal form limitations that can anchor solid-state infringement around specific process-derived solids.
What does US 6,875,872 claim, structurally?
Core claimed entity
All independent and dependent claims recite the same chemical backbone:
- Magnesium salt of
(−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
The optically defined center is the sulfinyl (sulfoxide) stereocenter, expressed as (−).
Claim 1 establishes the baseline scope
Claim 1 anchors the compound with a metal salt and optical purity threshold:
- Claim 1: Magnesium salt of the (−) benzimidazole sulfoxide at ≥ about 94% ee
Dependent claims tier optical purity
Claims 4, 7, and 10 raise the ee floors in steps:
- Claim 4: ≥ about 98.4% ee
- Claim 7: ≥ about 99.8% ee
- Claim 10: ≥ about 99.9% ee
Solid-state fallbacks exist
Claims 3, 6, 9, and 12 add a crystalline form limitation:
- Claim 3: crystal form (on the ≥94% ee compound)
- Claim 6: crystal form (on the ≥98.4% ee compound)
- Claim 9: crystal form (on the ≥99.8% ee compound)
- Claim 12: crystal form (on the ≥99.9% ee compound)
How broad are the claims in practice?
Scope drivers
The claims are constrained by four key dimensions:
- Exact salt identity: magnesium salt (Mg)
- Exact stereochemistry: (−) configuration
- Exact substitution pattern: 5-methoxy; 2-sulfinyl linkage to a (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl group; benzimidazole core
- Optical purity thresholds: at least about 94%, 98.4%, 99.8%, or 99.9% ee
- Optional solid form: crystalline form (dependent limitation)
What this excludes
The claim set does not read on:
- Non-magnesium salts (e.g., HCl, sulfate, sodium, potassium, or other metal salts)
- Opposite enantiomer ( (+) or racemate), or mixtures not meeting ee
- Alternative solvate/polymorph identities unless they still qualify as “crystalline form” under claim construction
- Substantially modified analogs (any change in the benzimidazole or pyridine substituent pattern breaks the structure recitation)
What it likely covers
The claims are most likely to cover:
- Commercial-scale purification products where the marketed API is delivered as Mg salt and sold/used at very high ee
- Solid API forms produced during enantiomeric resolution and salt formation, where crystallinity is inherent or process-controlled
Claim-by-claim scope mapping
| Claim |
Claim type |
What it adds |
Practical infringement hinge |
| 1 |
Independent |
Mg salt; (−) enantiomer; ≥ about 94% ee |
Product must be Mg salt of the exact stereodefined structure and meet ee threshold |
| 2 |
Dependent |
Restates compound of claim 1 with ≥94% ee (no new element) |
Provides redundancy; affects validity and claim interpretation structure |
| 3 |
Dependent |
Crystalline form |
Infringement requires crystallinity attribute for the claimed compound meeting claim 1/2 scope |
| 4 |
Dependent |
≥ about 98.4% ee |
Higher optical purity threshold narrows but increases enforceability for ultra-pure lots |
| 5 |
Dependent |
Restates claim 4 |
Redundancy; no new scope |
| 6 |
Dependent |
Crystalline form (on ≥98.4% ee) |
Solid-state criterion becomes mandatory |
| 7 |
Dependent |
≥ about 99.8% ee |
Very high ee requirement narrows product category |
| 8 |
Dependent |
Restates claim 7 |
Redundancy |
| 9 |
Dependent |
Crystalline form (on ≥99.8% ee) |
Solid state criterion plus ultra-pure ee |
| 10 |
Dependent |
≥ about 99.9% ee |
Tightest optical purity floor |
| 11 |
Dependent |
Restates claim 10 |
Redundancy |
| 12 |
Dependent |
Crystalline form (on ≥99.9% ee) |
Tightest crystallinity + ee combination |
Interpretive note: Claims 2, 5, 8, 11 appear to be pure restatements of the optical purity limitation in the parent claim, implying they function as additional claim redundancy rather than new technical coverage.
How to read the ee thresholds for freedom-to-operate
The optical purity ladders matter because many commercial processes deliver variable ee depending on step yield and batch specs.
Threshold structure
The patent claims step up as follows:
- ≥ about 94% ee (Claim 1)
- ≥ about 98.4% ee (Claim 4)
- ≥ about 99.8% ee (Claim 7)
- ≥ about 99.9% ee (Claim 10)
Infringement implications
For a manufacturer:
- If the marketed Mg salt API meets ≥94% ee, it likely falls within Claim 1 (regardless of whether it also meets 98.4/99.8/99.9).
- If a manufacturer markets an ee below 94%, it avoids Claim 1 but then risks process and downstream product inclusion depending on actual test results.
- If an entity markets crystalline product meeting the ee floor, Claims 3/6/9/12 become relevant as additional infringement hooks.
Operational consequence: Optical purity specifications and analytical method selection can become central to claim mapping, because each claim is defined by numerical ee cutoffs.
What is the likely patent landscape shape?
This patent’s place in the family
On the face of the claim text, US 6,875,872 looks like a salt-and-stereopurity patent rather than a general compound patent. This type of filing often sits downstream of:
- initial structure patents on the benzimidazole/sulfoxide scaffold, and/or
- process patents for resolution/enantiomeric enrichment, and/or
- earlier patents on “active” enantiomer forms, with this patent focusing on magnesium salt and very high ee crystalline solids.
Landscape inference from claim architecture
A claim set that:
- fixes a specific metal salt (magnesium),
- requires (−) stereochemistry, and
- escalates to ≥99.9% ee
often indicates the applicant’s strategy is to cover “best-in-class” product specs and solid forms that competitors struggle to match consistently.
Competitor risk patterns
In practice, competitors typically fail to design around these patents by:
- using different salts (they may try to switch to non-magnesium salts),
- lowering marketed ee below the patented floors (if feasible for efficacy/safety),
- selling amorphous rather than crystalline forms (if “crystalline form” is narrowly construed),
- using alternative polymorphs or solvate forms that avoid the “crystalline form” attribute (depends on claim construction and evidence).
Because the claims do not list particular polymorph IDs, “crystalline form” may be litigated around whether the product is sufficiently crystalline (not whether it is a named polymorph). That keeps the design-around surface more about salt identity and ee than about polymorph selection.
Design-around targets indicated by the claim set
1) Replace magnesium salt
Because the claims explicitly require magnesium salt, switching to another salt is the most direct structural avoidance vector.
2) Use a non-(−) stereochemical product
Switching to the opposite enantiomer or racemate would break the “(−)” and ee requirements, but only if the product does not meet the defined ee threshold.
3) Adjust marketed ee
A product sold at ee below about 94% avoids Claim 1. However, the feasibility depends on therapeutic performance and regulatory controls.
4) Avoid crystalline form qualification
If the competitor can sell an amorphous or non-crystalline solid while maintaining performance and stability, it may avoid dependent claims. Whether that avoids infringement on Claim 1 itself depends on whether the crystalline requirement is only in dependent claims (it is), meaning a competitor could still infringe Claim 1 even with an amorphous solid, provided it has the correct Mg salt and ee.
Key takeaways
- US 6,875,872 protects one exact magnesium-salt chemical species: (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.
- Optical purity is the central claim lever: the patent tiers from ≥ about 94% ee up to ≥ about 99.9% ee.
- “Crystalline form” adds dependent infringement hooks but does not eliminate baseline coverage because Claim 1 does not require crystallinity.
- Design-around emphasis should be on salt identity (magnesium) and ee specifications, not on polymorph naming alone.
- The landscape impact is likely highest for competitors who plan to market an ultra-enriched enantiomer Mg salt as a solid dosage ingredient.
FAQs
1) What is the independent claim scope in US 6,875,872?
Claim 1 covers the magnesium salt of the (−) substituted benzimidazole sulfoxide with ≥ about 94% enantiomeric excess.
2) Do the dependent claims change the compound structure?
No. Dependent claims refine scope by adding higher ee thresholds and/or the requirement that the compound is in a crystalline form.
3) Is crystallinity required to infringe Claim 1?
No. Crystallinity appears only in dependent claims (Claims 3, 6, 9, 12). Claim 1 itself has no crystalline limitation.
4) What is the highest optical purity threshold protected?
Claim 10 protects the compound at ≥ about 99.9% enantiomeric excess.
5) What is the cleanest structural design-around indicated by the claim text?
Switch away from the magnesium salt form, since magnesium is explicitly required in every claim reciting the compound.
References
[1] U.S. Patent 6,875,872 (claim text as provided by user).
